Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors' reply. Perez-Garcia JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al. Lancet 2025;405:1055-1056.

Read + Share

Amedeo Smart

Independent Medical Education

Perez-Garcia JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al. Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors' reply. Lancet 2025;405:1055-1056.
PMID: 40157800